Last reviewed · How we verify
Recombinant human tissue plasminogen activator
Recombinant human tissue plasminogen activator (rtPA) converts plasminogen to plasmin, which breaks down fibrin clots to restore blood flow.
Recombinant human tissue plasminogen activator (rtPA) converts plasminogen to plasmin, which breaks down fibrin clots to restore blood flow. Used for Acute ischemic stroke, Acute myocardial infarction, Pulmonary embolism.
At a glance
| Generic name | Recombinant human tissue plasminogen activator |
|---|---|
| Also known as | Alteplase, brand name: Actilyse, rt-PA |
| Sponsor | Angde Biotech Pharmaceutical Co., Ltd. |
| Drug class | Fibrinolytic agent / Thrombolytic |
| Target | Plasminogen / Fibrin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
rtPA is a serine protease that binds to fibrin in blood clots and catalyzes the conversion of plasminogen to plasmin, a potent fibrinolytic enzyme. Plasmin then degrades the fibrin matrix of the clot, leading to thrombolysis and restoration of blood flow. This mechanism makes it effective for acute thrombotic conditions where rapid clot dissolution is critical.
Approved indications
- Acute ischemic stroke
- Acute myocardial infarction
- Pulmonary embolism
Common side effects
- Bleeding (intracranial hemorrhage)
- Reperfusion arrhythmias
- Hypotension
- Allergic reactions
Key clinical trials
- Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) (PHASE2, PHASE3)
- Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion (PHASE2, PHASE3)
- Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion (EARLY_PHASE1)
- Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window. (PHASE3)
- Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window (PHASE4)
- Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden (PHASE4)
- rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2) (PHASE3)
- Intra-arterial Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Large Vascular Occlusion After Successful Mechanical Thrombectomy Recanalization (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |